Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q1 2023 Earnings Presentation
17 slides from Halozyme Therapeutics's earnings presentation, May 9, 2023
Slide 1: First Quarter 2023 Financial and Operating Results
First Quarter 2023 Financial and Operating Results NASDAQ: HALO May 9, 2023 1
Slide 2: Forward Looking Statements
Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future growth, financial performance (including the Company's financial outlo
Slide 3: What We Do: License Drug Delivery Platforms to Partners, and Commercialize Specialty Products
What We Do: License Drug Delivery Platforms to Partners, and Commercialize Specialty Products Drug Delivery Platform Technologies Commercial Portfolio ENHANZE® Auto-Injectors Specialty Products Commercially-Validated Commercialized & Sub-Cutaneous Delivery development stage devices for broad • 5 glo
Slide 4: Halozyme 2023 Growth Opportunities
Halozyme 2023 Growth Opportunities New Potential Royalty Clinical Advancement of New Partnership Opportunities Revenue Opportunity Partner Products with ENHANZE® • One ENHANZE® Deal • 2 Potential ENHANZE® SC Approvals in 2023 • SC Ocrelizumab Phase 3 • One High Volume Auto- Data Expected in 2023 Inj
Slide 5: The World Needs More Subcutaneous Large and Small Molecule Drug Delivery
The World Needs More Subcutaneous Large and Small Molecule Drug Delivery Potential benefits for Potential benefits for Healthcare System Patients and Caregivers (providers, nurses, pharmacists, payers) ▪ Potential to decrease healthcare costs: ▪ Decreased treatment burden – Less use of more costly h
Slide 6: ENHANZE: Durable Revenue Potential and Strong Future Growth Opportunities
ENHANZE®: Durable Revenue Potential and Strong Future Growth Opportunities Waves 1 & 2 Wave 3 Wave 4 Wave 5 5 Globally-Approved 10 Product Products 4 Product Candidates Candidates Launch Potential Launch Potential Launch Potential 2023-2025 2025-2027 2027+ Efgartigimod SC* 2 in Phase 3 New nominatio
Slide 7: Royalty Revenues: Projecting 23-26% Growth in 2023
Royalty Revenues: Projecting 23-26% Growth in WAV E 01 02 03 04 2023, Driven by ENHANZE® and Device Royalties Annual Total Royalty Revenue* ($M) Quarterly Royalty Revenue* ($M) 23-26% Year-over-Year Increase in 2023 43% Year-over-Year Increase in 1Q 2023 $445-$455 $106.0 $99.6 $99.6 $360.5 $85.3 $69
Slide 8: Wave 2: DARZALEX SC/FASPRO Share and Revenue Growth Continues
WAV E 01 02 03 04 Wave 2: Launch Growth Drivers DARZALEX SC/FASPRO® Share and Revenue Growth Continues DARZALEX FASPRO® Share of Total Total DARZALEX® Sales IV+SC ($B) 1 US DARZALEX® Sales2 18 $16.5 16 $15.3 $14.1 86% 88% 83% 85% 14 $12.8 80% 76% $11.3 72% 12 66% $9.6 10 $8.0 8 $6.0 6 $4.2 4 2 0 2Q
Slide 9: Wave 2: Phesgo Share and Revenue Growth Continues
WAV E 01 02 03 04 Wave 2: Launch Growth Drivers Phesgo® Share and Revenue Growth Continues Phesgo® Reduces Administration Time and Costs Phesgo® Global Conversion Rate1 • 85% of patients preferred Phesgo for Subcutaneous administration over the intravenous formulation of Perjeta and Herceptin • Pivo
Slide 10: Wave 3: Four Potential Launches 2023-2025
WAV E 01 02 03 04 Wave 3: Four Potential Launches 2023-2025 Products Disease Areas Milestones Potential Launch1 FDA PDUFA date extended to June 20, 2023 IV APPROVED gMyasthenia Gravis 2023 Efgartigimod for (gMG) Additional SC with ENHANZE® Other Indications gMyasthenia Gravis indication data readout
Slide 11: ENHANZE Partner Product Development Pipeline
ENHANZE® Partner Product Development Pipeline Wave 4 Pipeline Current Program/Product Indications Phase 1 Phase 2 Phase 3 Filed Wave 4 Amivantamab (Janssen) Solid malignancies Nivolumab+Relatlimab (BMS) Melanoma ARGX-117 (argenx) Multifocal motor neuropathy Teprotumumab-trbw (Horizon) Thyroid Eye Di
Slide 12: Testosterone Replacement Therapy Portfolio: Targeting >$100M XYOSTED Revenue in 2023
Testosterone Replacement Therapy Portfolio: Targeting to Generate >$100M XYOSTED Revenue in 2023 FOCUS FOCUS OPPORTUNITY ~8.5M TRX prescribed for testosterone replacement therapy in 2022 Once-a-week dosing 2X/daily oral Growing ~5% YOY administration Virtually painless subcutaneous injection using S
Slide 13: Halozyme Strategic and Capital Allocation Priorities
Halozyme Strategic and Capital Allocation Priorities Invest to Maximize Continue to Return Capital Identify Opportunities Revenue Growth and to Shareholders for External Growth Durability • ENHANZE® Second Plan: December 2021 • Continue to evaluate • Auto-injector innovation $750M 3-year share buyba
Slide 14: 1Q 2023 Financial Highlights
1Q 2023 Financial Highlights $ U.S. in Millions, except EPS (unaudited) 1Q 2023 1Q 2022 % Change Royalties $99.6 $69.6 43% Product sales, net $60.8 $22.1 175% Collaboration Revenues $1.7 $25.5 (93%) Total Revenues $162.1 $117.3 38% Cost of sales $35.2 $15.9 121% Amortization of intangibles $17.8 --
Slide 15: 2023 Financial Guidance Highlights
2023 Financial Guidance Highlights 2022 2023 • 23-28% YoY growth • Product Sales expected to increase due to full year Antares Total Revenue $660.1M $815M - $845M • contribution and increasing ENHANZE® API demand Total collaboration revenue expected to not exceed the levels in 2022, milestones to be
Slide 16: GAAP to Non-GAAP Reconciliation: Diluted EPS
GAAP to Non-GAAP Reconciliation: Diluted EPS Dollar amounts, as presented, are rounded. Consequently, totals may not add up. 1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the Antares acquisition. 2) Amount related to amortization of the i
Slide 17: GAAP to Non-GAAP Reconciliation: EBITDA
$ U.S. in Thousands GAAP to Non-GAAP Reconciliation: EBITDA $ U.S. in Millions Dollar amounts, as presented, are rounded. Consequently, totals may not add up. 17
Halozyme Therapeutics — Q1 2023 Earnings Presentation on 6ix